3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Other neoplasm
1
Gynecologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
15
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
2
Cardiotoxicity
2
Urogenital Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Inflammatory Breast Neoplasms
1
Heart Diseases
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Carcinoma In Situ
1
Breast Cancer Female
1
Brain Neoplasms
1
Interventions
Psychiatric Rehabilitation
8
Magnetic Resonance Spectroscopy
7
Gemcitabine
7
Capecitabine
7
pembrolizumab
6
Early Intervention, Educational
6
Drug Therapy
6
Cyclophosphamide
6
Methods
5
Therapeutics
4
Specimen Handling
4
Mental Status and Dementia Tests
4
Docetaxel
4
veliparib
3
selpercatinib
3
sargramostim
3
palbociclib
3
cediranib
3
Trastuzumab
3
Surveys and Questionnaires
3
Standard of Care
3
Radiotherapy
3
Paclitaxel
3
Oxaliplatin
3
Irinotecan
3
Fluorodeoxyglucose F18
3
Counseling
3
Cisplatin
3
Carboplatin
3
Bortezomib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
Atorvastatin
×
Breast
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn